Panbela Therapeutics Inc. (PBLA)
0.37
-0.06 (-13.95%)
At close: Feb 28, 2025, 3:46 PM
0.37
0.00%
Pre-market: Jan 02, 2025, 09:30 AM EST
Panbela Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.36M | 973.81K | 1.23M | 699.75K |
| Cost of Revenue | 25.65M | 35.73M | 10.01M | 5.75M | 4.32M | 3.89M | 6.02M | 5.17M | 5.44M | 595.15K | 558.47K | 691.8K | 550.54K |
| Gross Profit | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | 761.84K | 415.35K | 540.9K | 149.21K |
| Operating Income | -51.29M | -34.09M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | -75.4K | -194.32K | 282.8K | -104.5K |
| Interest Income | 123K | 14K | 1K | 17.00 | 2.19K | n/a | 1K | 2K | 8K | 4K | 18.41K | n/a | n/a |
| Pretax Income | -25.45M | -35.05M | -10.62M | -5.06M | -6.62M | -6.16M | -10.91M | -5.45M | -5.68M | -106.92K | -211.8K | 247.66K | -138.2K |
| Net Income | -25.26M | -34.93M | -10.13M | -4.77M | -6.2M | -5.91M | -10.37M | -5.11M | -4.93M | -107.04K | -212.02K | 247.38K | -138.31K |
| Selling & General & Admin | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.59M | 837.24K | 329.88K | 258.1K | 253.72K |
| Research & Development | 20.61M | 28.05M | 5.42M | 2.5M | 2.35M | 1.78M | 2.59M | 2.5M | 2.85M | 2.37K | 279.79K | n/a | n/a |
| Other Expenses | n/a | -682K | -602K | 605K | -99K | -508K | n/a | n/a | n/a | n/a | n/a | n/a | 253.72K |
| Operating Expenses | 25.65M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 837.24K | 609.67K | 258.1K | 253.72K |
| Interest Expense | -317K | 288K | 11K | 17K | 2.19M | 1.81M | 1.62M | 180K | 183K | 35.53K | 35.89K | 36.14K | 34.27K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -217K | n/a | n/a | n/a | n/a |
| Cost & Expenses | 51.29M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 1.43M | 1.17M | 949.9K | 804.26K |
| Income Tax | -186K | -116K | -488K | -295K | -415K | -254K | -536K | -341K | -756K | 121.00 | 220.00 | 284.00 | 115.00 |
| Shares Outstanding (Basic) | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.88K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
| Shares Outstanding (Diluted) | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.88K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
| EPS (Basic) | -232.43K | -40.75K | -20.77K | -14.8K | -26.1K | -1.52K | -3.49K | -1.97K | -4.2K | -892.03 | -1.77K | 2.06K | -1.15K |
| EPS (Diluted) | -232.43K | -40.75K | -20.77K | -14.8K | -26.1K | -1.52K | -3.49K | -1.97K | -4.2K | -892.03 | -1.77K | 2.06K | -1.15K |
| EBITDA | -51.29M | -34.76M | -10.61M | -5.15M | -4.42M | -1.76M | -6.02M | -5.17M | -5.12M | -75.4K | -194.32K | 289.44K | -101.4K |
| Depreciation & Amortization | n/a | 16.36K | 10.01K | 5.75K | 4.32K | 3.89K | 6.02K | 5.17K | 8K | 9.58K | 8.79K | 5.64K | 3.1K |